| Entries |
| Document | Title | Date |
|---|
| 20100286037 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING ACTIVE-PRINCIPLE ACTIVATORS OF ACONITASE - The present invention relates to a cosmetic or pharmaceutical, and in particular dermatological, composition comprising, in a physiologically suitable medium, active ingredients capable of activating aconitase. These active ingredients may be polypeptides or peptides, used alone or in combination with at least one other active ingredient. The invention also relates to the use of a cosmetic composition which protects mitochondria. The invention also relates to a cosmetic treatment process for protecting the skin and the appendages against external attacks and for combating skin ageing. | 11-11-2010 |
| 20100292142 | NOVEL NEUROTROPHIC FACTORS - The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same. | 11-18-2010 |
| 20100298214 | TREATMENT OF AUTOIMMUNE DISEASE - The present invention provides compositions, systems, and methods for identifying a patient suffering from and/or susceptible to autoimmune disease who might be likely to respond to treatment with CXCL12 and/or CXCR4 antagonists. The present invention provides novel CXCL12 and/or CXCR4 antagonists, methods of identifying novel CXCL12 and/or CXCR4 antagonists, and methods involving the use of these in the treatment of autoimmune disease. | 11-25-2010 |
| 20100298215 | SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE - The present invention provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides. Also disclosed are provides methods for using synthetic apolipoprotein E (ApoE)-mimicking peptides to reduce plasma glucose levels. Methods of using the disclosed apolipoprotein E (ApoE)-mimicking peptides to treat diabetes and diabetic complications are also disclosed. | 11-25-2010 |
| 20100298216 | Casein Derived Peptides And Uses Thereof in Therapy - Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the oS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases. | 11-25-2010 |
| 20100305031 | PEPTIDE HAVING AN EXTENDING ACTION FOR HALF-LIFE OF OBJECT PEPTIDE IN PLASMA - A peptide of the following (I) or (II).
| 12-02-2010 |
| 20100331248 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline (LSF) is an immunomodulator that reduces cytokine signaling and reduces the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of LSF and INGAP after pre-treatment with LSF is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 12-30-2010 |
| 20110034379 | Gastrin Compositions And Formulations, And Methods Of Use And Preparation - An embodiment of the invention provided herein is a pharmaceutical composition comprising a gastrin compound having an extended activity upon administration to a subject in comparison with native gastrin. Methods are provided of conjugating portions of the amino acid sequence of gastrin having functional ability to bind to the gastrin/CCK receptor, to various carrier moieties, including the use of amino acid spacer regions, and use of bifunctional cross-linking reagents. Methods of treating a diabetes patient with the compositions are provided. | 02-10-2011 |
| 20110039770 | INHIBITORS OF PROTEIN KINASE C ISOFORMS AND USES THEREOF - Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TIMs) of the present invention are capable of inhibiting one or more PKC isoforms. The TIMs can be designed to target a specific PKC isoform by selection of a PRE component that is shown to preferentially target that PKC isoform. The TIMs are useful as therapeutic agents in the treatment of PKC-related diseases and disorders, such as cancer, psoriasis, angiogenesis, restenosis, atherosclerosis, cardiovascular disease, hypertension, diabetes, neurological disorders, rheumatoid arthritis, kidney disorders, inflammatory disorders and autoimmune disorders. | 02-17-2011 |
| 20110039771 | SMALL HUMANIN-LIKE PEPTIDES - Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment. | 02-17-2011 |
| 20110046054 | ANTI DIABETIC PROTEIN - The present invention relates to a novel hypoglycemic/anti-hyperglycemic protein named ADMc1 purified from the seeds of | 02-24-2011 |
| 20110059889 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn - The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention. | 03-10-2011 |
| 20110071076 | NOVEL EXENDIN AGONIST COMPOUNDS - Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying. | 03-24-2011 |
| 20110082078 | Methods and compositions for treating neuropathies - Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression. | 04-07-2011 |
| 20110105394 | Amylin Derivatives - The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention. | 05-05-2011 |
| 20110118180 | METHOD OF TREATMENT OF DIABETES TYPE 2 COMPRISING ADD-ON THERAPY TO METFORMIN - A method for the treatment of diabetes mellitus type 2 comprising administering
| 05-19-2011 |
| 20110124556 | Insulin and IGF-1 Receptor Agonists and Antagonists - Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics. | 05-26-2011 |
| 20110124557 | BLOOD SUGAR-MODULATING POLYPEPTIDES - A blood sugar-modulating polypeptide, a pharmaceutical composition comprising the polypeptide, and a method for modulating blood sugar in a mammal comprising the administration of the polypeptide are provided. The polypeptide has a following amino acid sequence or a homologous amino acid sequence derived from the substitution, deletion, and/or addition of one or more amino acids therein: | 05-26-2011 |
| 20110144012 | SHORTENED GLUCAGON-LIKE PEPTIDE 1(SGLP-1) PREPARATION METHOD AND APPLICATION - This present invention a peptide consisting of 26 amino acids. The sequence is as follows: His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu. In comparison with the present GLP-1 and its similar compound, the shortened glucagon-like peptide 1(sGLP-1) in this invention has the following prominent advantages: 1. After reconstruction, the shortened peptide chain has stronger simulation to islet cell captors and stronger insulin secretion stimulation action; 2. the reconstructed simulation sequence can resist dipeptidyl peptidase decomposition by change of the second amino acid sequence from Ala to Gly or Ser to prolong its half time and enhance drug action; 3. To shorten the peptide chain leads to reduced synthesis cost. | 06-16-2011 |
| 20110172148 | PERIOSTIN-INDUCED PANCREATIC REGENERATION - A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed. Isolation of a nucleic acid encoding a periostin isoform, panc, is also taught. | 07-14-2011 |
| 20110183902 | PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION - Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity. | 07-28-2011 |
| 20110190201 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject - A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid hormones or metabolites or modulators thereof, wherein the at least one treatment regimen is determined based on pre-menopausal cyclic steroid hormone levels of the subject and on current cyclic steroid hormone levels of the subject, wherein the at least one treatment regimen is configured to maintain the subject's one or more steroid hormones or metabolites or modulators thereof at substantially physiological cyclic pre-menopausal levels. The method, device, or kit can be used for the treatment of a disease or condition in the mammalian subject. | 08-04-2011 |
| 20110190202 | Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes - Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction, age spots, acne, loss of cellular antioxidants, collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles including fine lines, oxidation, damage from radiation, damage from free radicals, damage from UV, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, liver spots, pigmented spots, dark circles under the eyes, skin pigmentation including darkened skin, blemishes, oily skin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, topical inflammation, disturbed keratinization, skin changes associated with aging, scalp dryness, skin depigmentation, intracellular dehydration, and combinations thereof; | 08-04-2011 |
| 20110212891 | AZEPINONE DERIVATIVES - The present invention relates to a compound represented by formula (I): wherein R | 09-01-2011 |
| 20110218143 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof. | 09-08-2011 |
| 20110230404 | Glycoproteins Produced in Plants and Methods of Their Use - Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein) for secretion. The methods result in increased recombinant glycosylated protein yields. Proteins produced according to these methods are disclosed. | 09-22-2011 |
| 20110251122 | POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY - A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth. | 10-13-2011 |
| 20110275562 | INHIBITION OF GLIADIN PEPTIDES - Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases. | 11-10-2011 |
| 20110288015 | Treatment of renal dysfunction and multiple myeloma using pacap compounds - The present invention relates to methods and compositions for the treatment, management, or prevention of multiple myeloma and/or renal dysfunction in mammals. The methods of the invention comprise the administration of an effective amount of one or more pituitary adenylate cyclase activating polypeptide (“PACAP”) compounds, which includes PACAP, vasoactive intestinal peptide (“VIP”), their agonists, analogs, fragments, or derivatives, having one or more PACAP activities. The invention also provides pharmaceutical compositions comprising one or more PACAP compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents useful in therapy for the treatment, management, or prevention of multiple myeloma and/or renal dysfunction. | 11-24-2011 |
| 20110312883 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 12-22-2011 |
| 20120010136 | USE OF CD31 PEPTIDES IN THE TREATMENT OF THROMBOTIC AND AUTOIMMUNE DISORDERS - The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders. | 01-12-2012 |
| 20120010137 | USE OF IXOLARIS, A TISSUE FACTOR INHIBITOR, FOR THE TREATMENT AND PREVENTION OF CANCER - The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits. | 01-12-2012 |
| 20120028894 | PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF - Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed. | 02-02-2012 |
| 20120028895 | Inhibiting Serum Response Factor (SRF) to Improve Glycemic Control - Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment. | 02-02-2012 |
| 20120094904 | FAD4, FAD5, FAD5-2, AND FAD6, NOVEL FATTY ACID DESATURASE FAMILY MEMBERS AND USES THEREOF - The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturase family members. The invention also provides recombinant expression vectors containing desaturase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (LCPUFAs), e.g., DHA. | 04-19-2012 |
| 20120108507 | Methods for In Vivo Cell Reprogramming - The present disclosure provides a new technology platform that converts one type of cells (substrate cells) to another type of cells (product cells). | 05-03-2012 |
| 20120135921 | TRIPETIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF - The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma. | 05-31-2012 |
| 20120157378 | Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes - Aspects of the invention include methods of predicting a subject's susceptibility to developing type 2 diabetes. Embodiments of the methods include obtaining a sex hormone-binding globulin (SHBG) level value for the subject, e.g., by detecting a SHBG plasma concentration and/or a SHBG polymorphism phenotype, and predicting the subject's susceptibility to developing type 2 diabetes from the obtained SHBG level value. Also provided are devices and kits that find use in practicing embodiments of the methods. In addition, methods of treating a subject for type 2 diabetes and/or preventing the onset of type 2 diabetes are provided. | 06-21-2012 |
| 20120165252 | Method of Regulating Glucose Metabolism, and Reagents Related Thereto - The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. | 06-28-2012 |
| 20120172297 | SYNTHETIC HUMAN GENES AND POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES - Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis. | 07-05-2012 |
| 20120190618 | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TRANS-BUCCAL MUCOSA TREATMENT OF POSTPRANDIAL HYPERGLYCAEMIA IN TYPE II DIABETES - The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes. | 07-26-2012 |
| 20120245086 | WNT10-Derived Peptide and Use Thereof - The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder using the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics. | 09-27-2012 |
| 20120264682 | TISSUE PROTECTIVE PEPTIDES AND USES THEREOF - Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor. Also provide herein are fragments, chimeras, as well as peptides designed to mimic the spatial localization of key amino acid residues within the tissue protective receptor ligands, e.g., EPO; methods for treating or preventing a disease or disorder using tissue protective peptides; and methods for enhancing excitable tissue function using tissue protective peptides. | 10-18-2012 |
| 20120264683 | USE OF AN FGF-21 COMPOUND AND A GLP-1 COMPOUND FOR THE TREATMENT OF OBESITY - The present invention provides methods of lowering body weight by administering an FGF-21 compound in combination with a GLP-1 compound. In addition, the present invention also provides methods to treat obesity by administering an FGF-21 compound in combination with a GLP-1 compound. The present invention also discloses combinations useful in the methods of the present invention. | 10-18-2012 |
| 20120283182 | Peptide Modulators of the deltaPKC Interaction with the d Subunit of F1F0 ATP Synthase/ATPase and Uses Thereof - The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF | 11-08-2012 |
| 20130005651 | DEATH ASSOCIATED PROTEIN 1 VARIANTS AND USE THEREOF FOR MODULATING AUTOPHAGY - The present invention relates to methods for the modulation of autophagy by altering the phosphorylation of Death Associated Protein (DAP1). The present invention further relates to methods of treating autophagy associated diseases comprising the suppression of autophagy by dephosphorylating DAP1. The invention further provides human DAP1 mutated at positions 3 and 51 with phospho-silencing residues and uses thereof in treating autophagy associated diseases. | 01-03-2013 |
| 20130023471 | METHODS TO RESTORE GLYCEMIC CONTROL - Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration. | 01-24-2013 |
| 20130040877 | LONG-ACTING Y2 RECEPTOR AGONISTS - The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y2 receptor modulation. | 02-14-2013 |
| 20130045916 | TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF - Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity. | 02-21-2013 |
| 20130065827 | Crystalline Peptide Epoxyketone Immunoproteasome Inhibitor - The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. | 03-14-2013 |
| 20130090289 | Method of Treatment of Type 2 Diabetes - Provided is a method of treating type 2 diabetes in a subject, comprising administering a polypeptide comprising thymosin, or an active fragment or variant thereof, preferably comprising or consisting of the peptide LKKTETQ (SEQ ID NO: 1). | 04-11-2013 |
| 20130109622 | NOVEL PROCESS FOR THE SYNTHESIS OF 37-MER PEPTIDE PRAMLINTIDE | 05-02-2013 |
| 20130137633 | mTOR KINASE-ASSOCIATED PROTEINS - The invention describes isolated mTOR-associated proteins (“mTOR-APs”) as well as isolated variants and fragments thereof and the isolated nucleic acids encoding them. The invention also describes vectors and host cells containing nucleic acid encoding an mTOR-AP polypeptide and methods for producing an mTOR-AP polypeptide. Also described are methods for screening for compounds which modulate mTOR-AP activity and methods for treating or preventing a disorder that is responsive to mTOR-AP modulation. | 05-30-2013 |
| 20130143804 | Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus - Methods for predicting a propensity for heart or kidney failure in a diabetic or pre-diabetic individual by determining the amount and/or molecular weight of islet amyloid polypeptide present in a sample from the individual are provided. | 06-06-2013 |
| 20130244934 | VIP FRAGMENTS AND METHODS OF USE - The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder. | 09-19-2013 |
| 20130261052 | INHIBITION OF MEMAPSIN 1 CLEAVAGE IN THE TREATMENT OF DIABETES - Proteases such as memapsin-1 are import enzymes, playing roles in a variety of diseases including diabetes. The inventors have developed inhibitors of memapsin 1 and methods of use therefore in the treatment of disease. | 10-03-2013 |
| 20130261053 | GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) COMPOSITIONS AND USE THEREOF - Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions. | 10-03-2013 |
| 20130267463 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING TH17-MEDIATED DISEASE COMPRISING POLY-GAMMA-GLUTAMIC ACID - Provided are a pharmaceutical use of poly-gamma-glutamic acid used for preventing or treating Th17-mediated diseases, a composition for preventing or treating Th17-mediated diseases comprising poly-gamma-glutamic acid as an active ingredient, and a method of preventing or treating Th17-mediated diseases using the same. The pharmaceutical composition is effective in inhibiting the differentiation of Th17 cells while promoting Treg cells, and, thus, can be useful in preventing or treating Th17-mediated diseases such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, and the like. | 10-10-2013 |
| 20130274185 | Pharmaceutical for Pseudo-Exercise Therapy - A pharmaceutical for pseudo-exercise therapy containing an adiponectin receptor 1 agonist compound as an active ingredient and changing the physiological state of muscle to a post-exercise one without applying an exercise stress to the muscle. | 10-17-2013 |
| 20130274186 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 10-17-2013 |
| 20130303448 | Therapeutic or Preventive Agent for Diabetes - A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly) | 11-14-2013 |
| 20130338067 | Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide - The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention. | 12-19-2013 |
| 20140005107 | APOLIPOPROTEIN AIV AS AN ANTIDIABETIC PEPTIDE | 01-02-2014 |
| 20140031281 | POLYMER-BASED SUSTAINED RELEASE DEVICE - This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | 01-30-2014 |
| 20140057843 | COMPOSITIONS FOR DIETARY HEALTH MANAGEMENT - This invention relates to a plurality of compositions for dietary health management and its use in the prevention or treatment of any one of the disease states in the group consisting of cardiovascular disease, inflammation and diarrhoea. Human evolution has been a very slow process in contrast to the relatively recent, rapid changes in our diet since the Neolithic revolution which marked the switch from hunter-gatherer to agricultural life-style around 10,000 years ago. Moreover our genome has not had time to evolve at the same pace and therefore it is postulated that our bodies will work more efficiently with an ancestral diet. In a first aspect of the invention, a plurality of compositions for the dietary health management system of a human being is provided, wherein the plurality of compositions comprise a daily diet of: (g) 1750 to 2750 kilocalories (7350 to 11550 kiloJoules); (h) have more than 1250, preferably more than 1450, more preferably more than 1650 mg gallic acid equivalents of polyphenols; (i) have more than 40, preferably more than 50, more preferably more than 60 g fibre; (j) have more than 130, preferably more than 150, more preferably more than 170 g protein (k) have 0 to 2, preferably 0 to 1.5, most preferably 0 to 1 g starch; and (I) have 0 to 5, preferably 0 to 2.5, most preferably 0 to 1 g lactose. | 02-27-2014 |
| 20140057844 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies. | 02-27-2014 |
| 20140057845 | COMPOSITION FOR TREATING, IMPROVING, OR PREVENTING PAIN - In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats. | 02-27-2014 |
| 20140073565 | CXCR4 AND ROBO1 EXPRESSION AS MARKERS FOR AUTOIMMUNE DIABETES - CXCR4 and ROBO-1 are biomarkers associated with type 1 diabetes. Expression of CXCR4 and ROBO-1 in peripheral CD3 T cells is substantially higher in patients with autoimmune diabetes (type 1 diabetes) than in non-diabetic patients. Therapies are disclosed for reducing the progression of type 1 diabetes, and to reduce the risk of developing type 1 diabetes in patients who are at risk of developing type 1 diabetes. | 03-13-2014 |
| 20140088004 | Hepatocyte Growth Factor Mimics as Therapeutic Agents - Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing. | 03-27-2014 |
| 20140088005 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K | 03-27-2014 |
| 20140088006 | Stem Cell Mobilization and Tissue Repair and Regeneration - Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gin-Val (SEQ ID NO: 1) effective to mobilize the stem cells. This method is useful for promoting preservation, repair, or regeneration of bodily tissue, or revascularization, in a patient in need of such treatment. Alternatively, the mobilized stem cells can be collected for transplant. | 03-27-2014 |
| 20140094408 | MEDICAMENT FOR TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERTENSION AND/OR METABOLIC SYNDROME - A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside. | 04-03-2014 |
| 20140094409 | ANTAGONIST FOR (PRO)RENIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION AND DIABETES - Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided. | 04-03-2014 |
| 20140107027 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 04-17-2014 |
| 20140113857 | TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9 - The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to β-catenin in vitro, in cellulo, and in vivo, disrupting the BCL-9/β-catenin interaction, and thereby interfering with deregulated Wnt/β-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer. | 04-24-2014 |
| 20140142036 | DIPEPTIDYL PEPTIDASE-4 INHIBITOR - The present invention aims to provide a DPP-4 inhibitor that is obtained by using a food as a raw material and that is suitable for oral ingestion from the viewpoints of flavor and absorbability, and a composition for the prevention and/or amelioration of diabetes which contains the DPP-4 inhibitor. The present invention provides a DPP-4 inhibitor obtained by treating an azuki bean or a kidney bean with a microorganism or a proteolytic enzyme produced by the microorganism. In particular, a preferable DPP-4 inhibitor can be obtained by hydrolyzing an azuki bean with a koji mold or a proteolytic enzyme derived from the koji mold to fragment a protein in the azuki bean. | 05-22-2014 |
| 20140155323 | POLYPEPTIDES, NUCLEIC ACID MOLECULE ENCODING POLYPEPTIDES, AND USES OF POLYPEPTIDES - A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes. | 06-05-2014 |
| 20140194354 | Methods for Treatment of Nephrotic Syndrome and Related Conditions - The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject. | 07-10-2014 |
| 20140235538 | Stabilized Insulin-like Growth Factor Polypeptides - The invention relates to stabilized polypeptides having an IGF-1 or IGF-2 sequence and an E-peptide sequence, where the natural physiological cleavage of the E-peptide from the IGF is prevented. | 08-21-2014 |
| 20140243263 | METHOD OF ENHANCING DIABETES RESOLUTION - Disclosed are compositions and methods for increasing diabetes resolution in a diabetic patient having undergone gastric restrictive surgery, entailing use of active agent that produces an incretin-like effect in the patient. | 08-28-2014 |
| 20140256625 | ANTI-AMYLOIDOGENIC, ALPHA-HELIX BREAKING ULTRA-SMALL PEPTIDE THERAPEUTICS - The invention provides ultra-small peptide inhibitors that are capable of preventing amyloid formation/amyloidosis. | 09-11-2014 |
| 20140274891 | METHOD OF GENERATING AN INDEX SCORE FOR MBL DEFICIENCY TO PREDICT CARDIODIABETES RISK - This application relates to methods of predicting susceptibility or likelihood of a clinically-relevant mannose-binding lectin (MBL)-deficient subject to develop a cardiovascular disease and/or cardiodiabetes. The methods include measuring MBL mass or concentration and, optionally, measuring MBL activity, at least one other biomarker and/or genotyping of MBL gene and its promoters; combining the information obtained into a calculated MBL-inclusive index score that involves mathematical transformation; and assigning a risk of cardiadiabetic status and clinical endpoints based on the determination and comparison of the MBL inclusive index to reference values from a population. | 09-18-2014 |
| 20140303079 | Delaying the Progression of Diabetes - Type-1 diabetes (T1 D) results from the autoimmune recognition of insulin producing β-cells within the pancreatic islet. The present application discloses a new protein, islet homeostasis protein (IHoP), that has a role in glucagon synthesizing-cell functions, and in post-onset T1 D islet differential expression of IHoP. Methods of delaying the onset of diabetes are disclosed, as well as compositions including an iHoP modulating agent. Also disclosed are methods of screening for iHoP modulating agents. | 10-09-2014 |
| 20140329746 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES - Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. | 11-06-2014 |
| 20140342982 | GENE THERAPY COMPOSITION FOR USE IN DIABETES TREATMENT - New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dogs or human beings. | 11-20-2014 |
| 20150011469 | METHOD OF TREATING DIABETES USING NON-GLYCOSYLATED APOLIPOPROTEIN A-IV - Methods for treating type two diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type two diabetes mellitus are disclosed, wherein the methods and compositions of the invention are based on the use of non-glycosylated apolipoprotein A-IV produced by a protein expression system, such as a bacterial expression system. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject in need thereof based on administering non-glycosylated apolipoprotein A-IV produced by a protein expression system. | 01-08-2015 |
| 20150011470 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS - The invention provides a compound of Formula (I) | 01-08-2015 |
| 20150018271 | HSP60 DERIVED PEPTIDES AND PEPTIDE ANALOGS FOR SUPPRESSION AND TREATMENT OF NON-AUTOIMMUNE DIABETES - The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60), and for suppression, prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™, a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression, prevention or treatment of T2D. | 01-15-2015 |
| 20150018272 | COMPOSITIONS AND METHODS OF USING PROISLET PEPTIDES AND ANALOGS THEREOF - Embodiments relate to proislet peptides, preferably HIP, that exhibit increased stability and efficacy, and methods of using the same to treating a pathology associated with impaired pancreatic function, including type 1 and type 2 diabetes and symptoms thereof. | 01-15-2015 |
| 20150038412 | ENHANCED GLYCEMIC CONTROL USING AD36E4ORF1 AND AKT1 INHIBITOR - This invention generally relates to methods for improving glycemic control by administering an Ad36 composition and an AKT1 inhibitor. | 02-05-2015 |
| 20150045296 | METHOD FOR TREATING DIABETIC RETINOPATHY - Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided. | 02-12-2015 |
| 20150051146 | HB-EGF INHIBITOR DERIVED FROM THE R DOMAIN OF DIPHTHERIA TOXIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF THE HB-EGF/EGFR PATHWAY - A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway. | 02-19-2015 |
| 20150065424 | VIP FRAGMENTS AND METHODS OF USE - The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder. | 03-05-2015 |
| 20150099698 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME - Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms. | 04-09-2015 |
| 20150126443 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 05-07-2015 |
| 20150133373 | TRANSMUCOSAL DELIVERY OF ENGINEERED POLYPEPTIDES - Formulations are provided that comprise compounds having inter alia good duration of action, high potency and/or convenient dosing regimens, and a permeation enhancer for transmucosal administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. The pharmaceutical compositions provided are suitable for methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system. | 05-14-2015 |
| 20150141329 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 05-21-2015 |
| 20150148290 | Macrocyclic Modulators of the Ghrelin Receptor - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 05-28-2015 |
| 20150299282 | A COMPOSITION FOR TREATING DIABETES OR DIABESITY COMPRISING OXYNTOMODULIN ANALOG - Disclosed are a composition for preventing or treating diabetes, diabesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels. | 10-22-2015 |
| 20150328184 | COMPOSITIONS AND METHODS FOR GLYCEMIC CONTROL OF SUBJECTS WITH IMPAIRED FASTING GLUCOSE - Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol. | 11-19-2015 |
| 20150343016 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF - The present invention describes the use of translation inhibitors for the treatment of cancer and other disorders. Described herein are translation-inhibiting compounds, and methods of using those compounds for the treatment of cancer and other disorders. In some aspects the compounds inhibit translation elongation at the ribosome. In some aspects the compounds are used alone or in combination with known therapies. | 12-03-2015 |
| 20150343022 | METHODS FOR TREATING METABOLIC DISORDERS USING FGF - The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver. | 12-03-2015 |
| 20150366846 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS - Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy. | 12-24-2015 |
| 20150366940 | SERPINS: METHODS OF THERAPEUTIC B-CELL REGENERATION AND FUNCTION - Compositions and methods of use are provided for improving β cell function and promoting pancreatic β cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof. | 12-24-2015 |
| 20150368299 | AMYLOID-BETA BINDING PROTEINS - The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any β form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided. | 12-24-2015 |
| 20160002310 | MODIFIED INGAP PEPTIDES FOR TREATING DIABETES - Novel INGAP peptides for prevention or treatment of diabetes are provided herein, as well as compositions and methods of use thereof. In particular, a 19 amino acid peptide of INGAP which possesses β-cell neogenesis and insulin potentiating activities and is sufficiently stable for in vivo use is described. | 01-07-2016 |
| 20160016997 | Stem Cell Mobilization and Tissue Repair and Regeneration - Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant. | 01-21-2016 |
| 20160031944 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS - The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo. | 02-04-2016 |
| 20160058734 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE - Compounds represented by the following formula (I); | 03-03-2016 |
| 20160074471 | USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE - The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor. | 03-17-2016 |
| 20160151455 | Synthetic Apolipoprotein E Mimicking Polypeptides And Methods Of Use | 06-02-2016 |
| 20160175246 | PHARMACEUTICAL FORMULATIONS | 06-23-2016 |
| 20160175400 | METHODS FOR TREATING METABOLIC DISORDERS AND OBESITY WITH GIP AND GLP-1 RECEPTOR-ACTIVE GLUCAGON-BASED PEPTIDES | 06-23-2016 |
| 20160200791 | GLP-1 Derivatives, and Uses Thereof | 07-14-2016 |
| 20190142963 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | 05-16-2019 |
| 20220135621 | NOVEL PEPTIDE AND USE THEREOF - The present invention relates to a peptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof and to the use thereof. The present invention is capable of effectively treating or preventing insulitis. Moreover, the present invention is capable of effectively treating or preventing type 1 diabetes. | 05-05-2022 |
